Azithromycin
≈ 9 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Azithromycin, sold under the brand names Zithromax (in oral form) and Azasite (as an eye drop), is an antibiotic medication used to treat several bacterial infections. These include middle ear infections, strep throat, pneumonia, traveler's diarrhea, sexually transmitted infection, and certain other intestinal infections. Along with other medications, it may also be used for malaria. It is administered by mouth, into a vein, or as topical treatment for the eye. Common side effects include nausea, vomiting, diarrhea and upset stomach. An allergic reaction, such as anaphylaxis, or a type of diarrhea caused by Clostridioides difficile is possible. Azithromycin causes QT prolongation that may cause life-threatening arrhythmias such as torsades de pointes. While some studies claim that no harm has been found with use during pregnancy, more recent studies with mice during late pregnancy has shown adverse effects on embryonic testicular and neural development of prenatal azithromycin exposure (PAzE). However, there need to be more well-controlled studies in pregnant women. Its safety during breastfeeding is not confirmed, but it is likely safe. Azithromycin is an azalide, a type of macrolide antibiotic. It works by decreasing the production of protein, thereby stopping bacterial growth.…
Azithromycin, sold under the brand names Zithromax (in oral form) and Azasite (as an eye drop), is an antibiotic medication used to treat several bacterial infections. These include middle ear infections, strep throat, pneumonia, traveler's diarrhea, sexually transmitted infection, and certain other intestinal infections. Along with other medications, it may also be used for malaria. It is administered by mouth, into a vein, or as topical treatment for the eye. Common side effects include nausea, vomiting, diarrhea and upset stomach. An allergic reaction, such as anaphylaxis, or a type of diarrhea caused by Clostridioides difficile is possible. Azithromycin causes QT prolongation that may cause life-threatening arrhythmias such as torsades de pointes. While some studies claim that no harm has been found with use during pregnancy, more recent studies with mice during late pregnancy has shown adverse effects on embryonic testicular and neural development of prenatal azithromycin exposure (PAzE). However, there need to be more well-controlled studies in pregnant women. Its safety during breastfeeding is not confirmed, but it is likely safe. Azithromycin is an azalide, a type of macrolide antibiotic. It works by decreasing the production of protein, thereby stopping bacterial growth. Azithromycin was discovered in Croatia in 1980 by the pharmaceutical company Pliva and approved for medical use in 1988. It is on the World Health Organization's List of Essential Medicines. The World Health Organization lists it as an example under "Macrolides and ketolides" in its Critically Important Antimicrobials for Human Medicine (designed to help manage antimicrobial resistance). It is available as a generic medication and is sold under many brand names worldwide. In 2023, it was the 64th most commonly prescribed medication in the United States, with more than 10 million prescriptions.
Pregnancy and breastfeeding
While some studies claim that no harm has been found with use during pregnancy, more recent studies with mice during late pregnancy has shown adverse effects on embryonic testicular and neural development of prenatal azithromycin exposure (PAzE). One recent study claims obvious fetus changes were observed under high-dose, mid-pregnancy and multi-course exposure. However, there need to be more well-controlled studies in pregnant women. The safety of the medication during breastfeeding is unclear. Reports indicate that because only low levels are found in breast milk and the medication has also been used in young children, it is unlikely that breastfed infants would have adverse effects.
Airway diseases
Azithromycin has beneficial effects in the treatment of asthma. It possesses antibacterial, antiviral, and anti-inflammatory properties which contribute to its effectiveness. Asthma exacerbations can be caused by chronic neutrophilic inflammation, and azithromycin is known to reduce this type of inflammation due to its immunomodulatory properties. The recommended dosage for controlling asthma exacerbations with azithromycin is either 500 mg or 250 mg taken orally as tablets three times a week. In adults with severe asthma, low-dose azithromycin may be prescribed as an add-on treatment when standard therapies such as inhaled corticosteroids or long-acting β 2 agonists are not sufficient. Long-term use of azithromycin in patients with persistent symptomatic asthma aims to decrease the frequency of asthma exacerbations and improve their quality of life. While both its anti-inflammatory and antibacterial effects play important roles in treating asthma, studies suggest that responsiveness to azithromycin therapy depends on individual variations in lung bacterial burden and microbial composition, collectively referred to as the lung microbiome. The richness (diversity) of the lung microbiome has been identified as a key factor in determining the effectiveness of azithromycin treatment. Azithromycin has significant interactions with the patient's microbiome. Long-term use of azithromycin reduces the presence of H. influenzae bacteria in the airways but also increases resistance against macrolide antibiotics. The specific pharmacological mechanisms through which azithromycin interacts with the patient's microbiome remain unknown research continues to explore how changes in microbial composition influence drug efficacy and patient outcomes. Azithromycin appears to be effective in the treatment of chronic obstructive pulmonary disease through its suppression of inflammatory processes. Azithromycin is potentially useful in sinusitis via this mechanism. Azithromycin is believed to produce its effects through suppressing certain immune responses that may contribute to inflammation of the airways.
Society and culture
)]]
Usage
In 2010, azithromycin was the most prescribed antibiotic for outpatients in the US, whereas in Sweden, where outpatient antibiotic use is a third as prevalent, macrolides are only on 3% of prescriptions. In 2017, and 2022, azithromycin was the second most prescribed antibiotic for outpatients in the United States. In 2022, it was the 78th most commonly prescribed medication in the United States, with more than 8 million prescriptions.
Research
Azithromycin is researched for its supposed anti-inflammatory and immunomodulatory properties, which are believed to be exhibited through its suppression of proinflammatory cytokines and enhancing the production of anti-inflammatory cytokines, which is important in dampening inflammation. Cytokines are small proteins that are secreted by immune cells and act in the immune response. Studies suggest that azithromycin can decrease the release of pro-inflammatory cytokines such as TNF-alpha, IL-1β, IL-6, and IL-8 while increasing the levels of anti-inflammatory cytokine IL-10. By decreasing the number of pro-inflammatory cytokines, azithromycin probably controls potential tissue damage during inflammation. These effects are believed to be due to azithromycin's ability to suppress a transcription factor called nuclear factor-kappa B (NF-κB) resulting in blockade of inflammatory response pathways downstream from NF-κB activation leading to decreased chemokine receptor CXCR4 signaling causing reduced inflammation. Despite the efficiency of treating rosacea with azithromycin, the exact mechanism of why azithromycin is effective in treating rosacea are not completely understood. It is unclear whether its antibacterial or immunomodulatory properties or a combination of both mechanisms contribute to its efficacy. Azithromycin may prevent mast cell degranulation and thus can suppress inflammation of dorsal root ganglia through various signaling pathways such as decreased numbers of CD4 + T cells which are particularly relevant since they mediate the response of hair follicle antigens. Inflammation in rosacea is thought to be associated with increased production of reactive oxygen species (ROS) by inflammatory cells. The ability of azithromycin to decrease ROS production can help reduce oxidative stress and inflammation, but this remains speculation. The therapeutic role of azithromycin has been explored in various diseases such as cystic fibrosis exacerbation, burn injury-induced lung injury, asthma, chronic obstructive pulmonary disease, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in COVID-19 infection. Despite early evidence showing azithromycin slowed down coronavirus multiplication in laboratory settings, further research indicates it to be ineffective as a treatment for COVID-19 in humans. Azithromycin in conjunction with chloroquine or hydroxychloroquine has been associated with deleterious outcomes in COVID-19 patients, including drug-induced QT prolongation. After a large-scale trial showed no benefit of using azithromycin in treating COVID-19, the UK's National Institute for Health and Care Excellence (NICE) updated its guidance and no longer recommends the medication for COVID-19. Azithromycin has been studied in the treatment of chronic fatigue syndrome (CFS) and has been reported to improve or even resolve symptoms in some cases. However, these studies have been described as being of very low quality. In any case, the beneficial effects might be by eradication of chronic bacterial infections that are possibly contributing to or causing CFS or by the immunomodulatory effects of azithromycin. Azithromycin therapy in cystic fibrosis patients yields a modest respiratory function improvement, reduces exacerbation risk, and extends time to exacerbation up to six months; still, long-term efficacy data is a subject of ongoing research. Potential benefits of azithromycin therapy is azithromycin's good safety profile, minimal treatment burden, and cost-effectiveness, but the drawbacks are gastrointestinal side effects with weekly dosing, which are ameliorated by a split dose regimen. The potential role of azithromycin in inhibiting the autophagic destruction of non-tuberculous mycobacteria (NTM) within macrophages is under study. This mechanism may contribute to the observed correlation between long-term macrolide monotherapy and an increased risk of NTM infection and the emergence of macrolide-resistant strains. Azithromycin's interference with autophagy could potentially predispose patients with cystic fibrosis to mycobacterial infections. Despite repeated refutations of a direct association between azithromycin use and NTM infection, there remains a high level of concern regarding the potential for the development of NTM strains resistant to macrolides. Azithromycin has been shown to be an effective preventive measure against many postpartum infections in mothers following planned vaginal births; still, its impact on neonatal outcomes remains inconclusive and is the subject of ongoing research.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1367373742 under CC BY-SA 4.0; modifications have been made.